Report Compiler 1

Req ID:  163232

Tranent, GB, EH33 2NE

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

We are seeking a Report Compiler for our Administration & Reporting department located in Elphinstone, Tranent. 
The Administration and Reporting department is responsible for collating, tabulating and reporting scientific data from safety assessment studies and using reporting software to compile the study report to the standards required by the Company, its clients and international regulatory authorities.
Key responsibilities:
•    You will work closely with study management and Quality Assurance.
•    You will be responsible for the timely collation and tabulation of data from safety assessment studies to meet tight deadlines.
•    You will have responsibility for the development of reports to the standards required by the Company, its clients and international regulatory authorities.
•    You will be responsible for the quality control of own work and the work of others

Applicants should have:
•    University entrance standard educational qualifications. A degree is welcome, but not essential.
•    High degree of IT literacy i.e. extensive experience in use of word-processing, electronic text production and report writing is essential
•    Proven experience of working within given timescales with excellent attention to detail
•    Effective written and verbal communication skills
•    Managing own workloads and prioritising conflicting responsibilities

Salary banding for this position is £24,876.69. 
The closing date is 31 January 2023. 

About Discovery
Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 350 patents and 80 preclinical drug candidates delivered to our sponsors in the past 17 years. Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.